Carregant...
Rapid desensitization for brentuximab vedotin (Adceteris(®)) allergy: a case report
BACKGROUND: Brentuximab vedotin (BV) is an antibody–drug conjugate formed by an anti-CD30 chimeric IgG(1) conjugated with monomethyl-auristatin-E. BV targets the CD30(+) cells, which characterize Hodgkin lymphoma as well as anaplastic large cell lymphoma. Once bound to the CD30(+) cells BV exerts it...
Guardat en:
| Publicat a: | Clin Mol Allergy |
|---|---|
| Autors principals: | , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioMed Central
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6205792/ https://ncbi.nlm.nih.gov/pubmed/30386181 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12948-018-0100-0 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|